Generic placeholder image

Central Nervous System Agents in Medicinal Chemistry


ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry

Author(s): Ying Liu, Naijing Li, Ling Zhou, Qing Li and Wei Li

Volume 14, Issue 2, 2014

Page: [113 - 120] Pages: 8

DOI: 10.2174/1871524915666141216161246

Price: $65


Objectives: Alzheimer’s disease (AD) is the main cause of gradual cognitive impairment in elderly individuals. This highlights the need of obtaining biomarkers to identify features that are different among mild cognitive impairment (MCI), AD and cognitively normal (CN) individuals. Design and methods: Ultra-performance liquid chromatography (UPLC)/mass spectrometry (MS) was employed to find the metabolic changes in plasma samples obtained from AD, MCI and CN individuals. Based on principal component analysis (PCA), the metabolic differences among AD, MCI and CN subjects were identified. Results: The PCA of UPLC/MS spectra indicated metabolic differences among AD, MCI and CN subjects. The peak intensities of progesterone, lysophos- phatidylcholines (LPCs), tryptophan, L-phenylalanine, dihydrosphingosine and phytosphingosine in the plasma of the MCI and AD subjects were significantly different from the CN subjects. Furthermore, the peak intensities of tryptophan, LPCs, dihydrosphingosine in the plasma of the AD subjects were significantly lower compared to the MCI subjects. Conclusion: Our data provide a link between metabolite imbalance and AD, and suggest that metabolomics can be used to reveal the early disease mechanisms occurred in the progression from CN to MCI and AD.

Keywords: Alzheimer's disease, UPLC-MS, mild cognitive impairment, dementia.

Next »
Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy